Evoke Pharma Inc (EVOK)
4.41
-0.09
(-2.00%)
USD |
NASDAQ |
Nov 22, 15:02
Evoke Pharma Profit Margin (Quarterly): -49.45% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -49.45% |
| June 30, 2024 | -49.67% |
| March 31, 2024 | -91.03% |
| December 31, 2023 | -118.6% |
| September 30, 2023 | -108.4% |
| June 30, 2023 | -165.1% |
| March 31, 2023 | -276.8% |
| December 31, 2022 | -226.4% |
| Date | Value |
|---|---|
| September 30, 2022 | -242.0% |
| June 30, 2022 | -483.6% |
| March 31, 2022 | -519.5% |
| December 31, 2021 | -463.8% |
| September 30, 2021 | -211.7% |
| June 30, 2021 | -968.0% |
| March 31, 2021 | -2.88K% |
| December 31, 2020 | -9.85K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-9.85K%
Minimum
Dec 2020
-49.45%
Maximum
Sep 2024
-1.04K%
Average
-234.2%
Median
Profit Margin (Quarterly) Benchmarks
| Repligen Corp | -0.42% |
| Eli Lilly and Co | 8.48% |
| MEI Pharma Inc | -- |
| Revance Therapeutics Inc | -63.65% |
| NovaBay Pharmaceuticals Inc | -49.65% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -433.1% |
| Return on Assets | -57.27% |
| Return on Invested Capital | -95.76% |
| Gross Profit Margin (Quarterly) | 96.08% |
| Operating Margin (Quarterly) | -48.44% |